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reduces pancreatic cancer growth when
combined with gemcitabine
Dannel Yeo1, Hong He1, Oneel Patel1, Andrew M. Lowy2, Graham S. Baldwin1 and Mehrdad Nikfarjam1*
Abstract
Background: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment
options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing
evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cancer, its role has not been
fully elucidated. This study aimed to characterise the expression and functional relevance of PAK1 in pancreatic
cancer.
Methods: PAK1 expression was measured in pancreatic cancer specimens by immunohistochemistry and in
pancreatic cancer cell lines by western blotting. The effect of inhibition of PAK1 by either shRNA knock-down (KD),
or by a selective inhibitor, FRAX597, alone or in combination with gemcitabine, on cell proliferation and migration/
invasion was measured by thymidine uptake and Boyden chamber assays, respectively. The effect on tumour
growth and survival was assessed in orthotopic murine models.
Results: PAK1 was expressed in all human pancreatic cancer samples tested, an7d was upregulated in all pancreatic
cancer cell lines tested. PAK1 KD inhibited pancreatic cancer cell growth and survival, and increased sensitivity to
gemcitabine treatment. AKT activity and HIF1α expression were also inhibited. FRAX597 inhibited pancreatic cancer
cell proliferation, survival, and migration/invasion. When combined with gemcitabine, FRAX597 synergistically
inhibited pancreatic cancer proliferation in vitro and inhibited tumour growth in vivo.
Conclusions: These results implicate PAK1 as a regulator of pancreatic cancer cell growth and survival. Combination of
a PAK1 inhibitor such as FRAX597 with cytotoxic chemotherapy deserves further study as a novel therapeutic approach
to pancreatic cancer treatment.
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Background
Pancreatic ductal adenocarcinoma remains one of the
most lethal of all solid tumours. It is the fourth leading
cause of cancer-related mortality in Australia and the
United States and is expected to become the second
leading cause of cancer-related deaths by 2030, based on
current management with no significant treatment im-
provements [1]. The 5-year survival rate is less than 5 %
and has not improved over the past few decades [2].
Although combinational chemotherapies exist such as
FOLFIRINOX and gemcitabine with nab-paclitaxel, as a
single agent, gemcitabine remains the standard of care
for the treatment of pancreatic cancer in most countries
[3]. Gemcitabine targets rapidly replicating cells by
inhibiting DNA synthesis, but intrinsic and acquired
chemoresistance is common. The limited treatment regi-
mens and predicted increase in cancer-related mortality
highlight the urgent need for the development of effect-
ive therapies based on our understanding of the molecu-
lar mechanisms involved in pancreatic cancer.
The most frequent and earliest mutation in pancreatic
cancer is the Kras mutation, present in over 95 % of
pancreatic cancer patients [4]. This mutation results in a
constitutively active p21 protein, Ras, which can activate
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a number of signalling pathways, including other p21
proteins such as Cdc42 and Rac, through direct and in-
direct mechanisms [5]. These p21 proteins can then acti-
vate the p21-activated kinases (PAKs). Although there is
evidence for the activation of PAKs by Kras-driven path-
ways, other non-Kras-driven pathways or indirect Kras
mechanisms may also activate PAKs.
PAKs are a family of non-receptor serine/threonine
kinases, which mediate many effector functions from cell
cycle and DNA transcription to cell adhesion and motil-
ity [6]. There are six isoforms of PAKs, divided into two
groups: Group 1 contains PAK1, 2 and 3, and Group 2
contains PAK4, 5 and 6. Of the six isoforms, PAK1 is the
best documented and has been found to be up-regulated
in a number of cancers [7], including pancreatic cancer
[8]. PAK1 is also up-regulated in pancreatic cancer cell
lines when expression of MUC13, a transmembrane
mucin, is increased [9]. We have previously found that a
non-selective PAK inhibitor, glaucarubinone, reduced
pancreatic cancer growth, and that treatment in combin-
ation with gemcitabine resulted in synergistic inhibition
[10]. The role of PAK1 in pancreatic cancer and its
therapeutic potential have not been fully elucidated.
FRAX597 is a small-molecule pyridopyrimidinone that
targets group 1 PAKs through binding to the ATP-
binding site [11]. Although it has been found to prefer-
entially target group 1 PAKs, FRAX597 also inhibits
other kinases such as RET, YES1, TEK, and CSF1R [12].
Of the group 1 PAKs, FRAX597 selectively inhibits
PAK1 with a kinase IC50 of 8 nM, compared to 13 nM
and 19 nM with PAK2 and PAK3, respectively. No inhib-
ition of the group 2 PAKs was observed [11]. FRAX597
inhibits proliferation in neurofibromatosis type 2 (NF2)-
associated schwannomas [12], but has not been tested
previously in pancreatic cancer. This study aimed to elu-
cidate the role of PAK1 in pancreatic cancer, by examin-
ing the effects of reduction of PAK1 expression by
shRNA knock-down, or PAK1 activity with the select-
ive inhibitor FRAX597, on the growth and migration/
invasion of pancreatic cancer cell lines in vitro, and
in orthotopic murine models in vivo, alone and in
combination with gemcitabine.
Methods
Cells and reagents
The human PANC-1, MiaPaCa-2 and BxPC-3 pancreatic
cancer cell lines (American Type Culture Collection,
Manassas, VA) and the murine Pan02 (Division of
Cancer Treatment and Diagnosis Tumor Repository,
NCI, Frederick, MD), and LM-P (obtained from Andrew
Lowy (Moores Cancer Center, University of California,
San Diego, CA) [13]) pancreatic cancer cell lines were
cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10 % FBS (fetal bovine
serum: Hyclone Laboratories Inc., Scoresby, Australia).
Normal immortalised human pancreatic duct epithelial
(HPDE) cells (obtained from M.S Tsao (Ontario Cancer
Institute, Ontario, Canada)) were cultured in Keratinocyte
serum-free medium supplemented with bovine pituitary
extract (BPE) and epidermal growth factor (EGF). All cells
were cultured in a 37 °C incubator with 5 % CO2. Cells
were tested regularly for mycoplasma contamination and
were not passaged more than 30 times or for more than
6 months after resuscitation.
FRAX597 was purchased from SYNthesis (Parkville,
Australia) and gemcitabine was purchased from Sigma-
Aldrich (Castle Hill, Australia).
Immunohistochemistry (IHC) on human pancreatic cancer
samples
Human tissue collection was approved by the Austin
Health Human Research Ethics Committee (H2013/
04953) and informed consent was obtained from all par-
ticipants. Samples of 10 human pancreatic cancers and
adjacent normal pancreas were collected from patients
undergoing pancreatic cancer resection at Austin Health,
and confirmed to have pancreatic ductal adenocarcin-
oma by two independent pathologists. For PAK1 IHC,
sample sections were incubated with 3 % hydrogen per-
oxide in methanol for 10 min at room temperature to
quench endogenous peroxidase activity. Antigens were
retrieved by incubation in 10 mM citrate buffer and
blocked in 5 % horse serum. Sections were incubated
with antibody against PAK1 (Santa Cruz Biotechnology,
Dallas, TX) or IgG. Sections were visualised using an
ENvision Plus polymer-based detection kit (Dako, Botany,
Australia). The slides were then counter-stained and
images were taken with a NIKON Coolscope (Coherent
Scientific, Hilton, Australia).
shRNA transfection
To obtain PAK1 knock-down (KD) clones, PANC-1 and
MiaPaCa-2 cells were transfected with SureSilencing
shRNA plasmids for human PAK1 (SABioscience,
Doncaster, Australia), or with a scrambled sequence
as a negative control (NC), using Lipofectamine2000
(Invitrogen, Mulgrave, Australia), according to the
manufacturer's instructions. Stable clones were selected
with geneticin (G418; 1 mg/ml). PAK1 protein expression
was detected by western blot.
Western blot
Proteins in cell lysates were detected with antibodies
against phospho-PAK1 (Santa Cruz Biotechnology),
PAK1, phospho-AKT, AKT, HIF1α (BD Biosciences,
North Ryde, Australia), and GAPDH. Antibodies were
from Cell Signalling Technology (Arundel, Australia),
unless otherwise stated. Bound antibodies were visualized
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using ECL reagents (GE Healthcare, Amersham, UK), and
the density of each band was analysed using Multigauge
computer software (Berthold, Bundoora, Australia). HIF1α
expression was determined in cells cultured under nor-
moxia or hypoxia (1 % O2).
Cell proliferation, cell survival and combination index
Cell proliferation and survival was measured using 3H-
thymidine incorporation and withdrawal assays, respect-
ively, as previously described [14]. Growth curves were
fitted based on a log-scale using MATLAB (MathWorks,
Natick, MA) and differences in proliferation were evalu-
ated by comparison of growth rates (expressed as %/h).
Assessment of proliferation with FRAX597 and the com-
bination of FRAX597 with gemcitabine was measured as
previously described [10]. For assessment of cell survival
with FRAX597, cells were seeded with increasing con-
centrations of FRAX597 for 24 h without serum.
The combined effects of FRAX597 and gemcitabine
were evaluated using the Chou-Talalay method [15] as
previously described [10]. The CalcuSyn program (Biosoft,
Cambridge, UK) was used to calculate the combination
index (CI) for each drug affected fraction (Fa). The CI
value is interpreted as: <1, synergistic; =1, additive; >1,
antagonistic.
Cell migration/invasion
Cell migration/invasion was measured using the
Transwell Boyden chamber assay as previously de-
scribed [14]. Cells were seeded into the upper chambers of
the inserts (ThinCert™, 8 μm pore size; Greiner Bio-One,
Frickenhausen, Germany) with increasing concentrations
of FRAX597. After 24 h, membranes were fixed and
stained with Quick-Dip (Fronine, Riverstone, Australia)
and 24 fields were counted at 40 times magnification
using a NIKON Coolscope.
Murine orthotopic pancreatic cancer model
All mice experiments were approved by the Austin
Health Animal Research Ethics Committee (A2013/
04898). Pan02 cells were implanted orthotopically in the
pancreatic head or tail as previously described [16]. For
assessment of tumour growth, 28 mice were implanted
with cells in the pancreatic tail and monitored for
30 days. 7 mice per treatment group were randomly allo-
cated to the four treatment groups: control, intraperito-
neal (i.p.) injection of saline every other day; FRAX597
alone, FRAX597 (3 mg/kg) i.p. every other day; gemcita-
bine alone, gemcitabine (40 mg/kg) i.p. twice weekly;
and combination of FRAX597 and gemcitabine, follow-
ing the individual treatments as described above. A sin-
gle investigator measured the dimensions of all tumours,
at the endpoint, using micro-calipers, in a double-
blinded manner. Tumour volume was calculated using
the formula for ellipsoid tumours: V = L x W x H x (π/6)
where L was the longest distance from right to left; W, the
largest dorsal/ventral diameter; and H, the largest rostral/
caudal diameter. For assessment of survival, 54 mice were
implanted with cells in the head of the pancreas. Mice
were monitored based on health score for up to 45 days
and euthanased when a poor health score was reached.
Mice were treated with either control, gemcitabine alone,
or combination of FRAX597 and gemcitabine, as de-
scribed above. An initial study was undertaken with 24
mice, with 12 mice per group for control or gemcitabine
treatment alone. A second study was undertaken with 30
mice, with 13 mice per group for gemcitabine alone or
combination treatment, and the remaining 4 mice allo-
cated to the control group. A collated Kaplan-Meier sur-
vival curve was plotted, and the two studies were analysed
together using stratified Cox regression analysis (SPSS;
IBM, New York, NY).
Statistical analysis
All values are expressed as means ± standard error. Ex-
periments were done in duplicate and data collated from
three independent experiments. Results were analysed
using student’s t-test or one-way ANOVA (SPSS). Differ-
ences between two means with p < 0.05 were considered
significant.
Results
PAK1 is expressed in human pancreatic cancer and
upregulated in pancreatic cancer cell lines
PAK1 staining of pancreatic ductal adenocarcinoma
cells was observed in all 10 human pancreatic cancer
samples tested (Fig. 1a). In corresponding normal pan-
creas samples, islet cells stained for PAK1, however,
staining was absent in acinar and ductal epithelial
cells. Expression of PAK1, and of the phosphorylated,
active form of PAK1, was detected in low levels in
the normal HPDE cell line and was significantly
lower when compared to all the pancreatic cancer
cell lines. All human and murine pancreatic cancer
cell lines tested expressed phosphorylated and total
PAK1 (Fig. 1b).
Inhibition of PAK1 by shRNA knock-down decreases
proliferation and survival of pancreatic cancer cells
The PAK1 protein concentrations in two PANC-1 PAK1
KD clones (2.05 and 2.10) were decreased to 22 % and
24 %, respectively, of the PAK1 protein concentrations
of the corresponding NC cells, which had been trans-
fected with scrambled sequences (Fig. 2a). Similarly, the
PAK1 protein concentrations in two MiaPaCa-2 PAK1
KD clones (3.09 and 3.12) were decreased to 11 % and
9 %, respectively, of the PAK1 protein expression of the
corresponding NC cells (Fig. 2b). The proliferation rate
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was significantly reduced in both PANC-1 (Fig. 2c) and
MiaPaCa-2 (Fig. 2d) PAK1 KD cells compared to the
corresponding NC cells. The growth rate of two clones
of PANC-1 PAK1 KD cells (1.9 %/h and 2.1 %/h) was
significantly less than two clones of NC cells (2.4 %/h
and 2.6 %/h) (Table 1). A similar difference was observed
in the MiaPaCa-2 PAK1 KD cells.
Inhibition of PAK1 by shRNA knock-down sensitises
pancreatic cancer cells to gemcitabine
Proliferation of PANC-1 (Fig. 2e) and MiaPaCa-2
(Fig. 2f ) PAK1 KD cells in the presence of gemcitabine
at concentrations of 20 nM and 50 nM was inhibited to
a greater extent than the corresponding NC cells. The
IC50 values of two clones of PANC-1 PAK1 KD cells
(20 nM and 21 nM) (Table 1), were significantly less
than the values for NC cells (26 nM and 39 nM).
Similarly, the IC50 values of two clones of MiaPaCa-2
PAK1 KD cells (26 nM and 25 nM) (Table 1) were
significantly less than the values for NC cells (29 nM
and 28 nM).
Inhibition of PAK1 by shRNA knock-down reduces AKT
activity and HIF-1α expression
AKT activity was significantly reduced in two clones of
PANC-1 PAK1 KD cells, by 22 % and 31 % (Fig. 3a), and
in two clones of MiaPaCa-2 PAK1 KD cells by 24 % and
33 % (Fig. 3b). HIF1α expression was significantly re-
duced in two clones of both PANC-1 (Fig. 3c) and
MiaPaCa-2 (Fig. 3d) PAK1 KD cells compared to the NC
cells under either normoxia or hypoxia.
FRAX597 decreases proliferation and migration/invasion
in pancreatic cancer cell lines
FRAX597 inhibited proliferation in all pancreatic cancer
cell lines in a dose-dependent manner (Fig. 4a), with
IC50 values between 650 nM for BxPC-3 cells and
2.0 μM for PANC-1 cells (Table 2). Similarly, FRAX597
a
b
Pancreatic Cancer
PAK1 IHC
Pancreatic Cancer
Negative CT IHC
Normal Pancreas
PAK1 IHC
Fig. 1 PAK1 is up-regulated in pancreatic cancer specimens and pancreatic cancer cell lines. (a) Acinar and ductal cells in normal pancreas are
not stained for PAK1 by immunohistochemistry (IHC), but islet cells (arrow) are positive. Magnification: x200. Pancreatic ductal adenocarcinomas
stain more strongly for PAK1 than the negative control (CT). Magnification: x100. (b) The normal pancreas cell line, HPDE, expressed low levels of
phospho-PAK1 (active form) and PAK1 as detected by western blotting. All pancreatic cancer cell lines, MiaPaCa-2, PANC-1, BxPC-3, Pan02 and
LM-P expressed phospho-PAK1 and PAK1. The data represent mean ± SEM, summarised from three independent experiments. * p < 0.05; ** p < 0.01,
compared to all other pancreatic cancer cell lines
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inhibited migration and invasion in all pancreatic cancer
cell lines in a dose-dependent manner (Fig. 4b), with
IC50 values between 105 nM for MiaPaCa-2 cells and
605 nM for Pan02 cells (Table 2). FRAX597 inhibited
survival of LM-P cells in the absence of FBS in a dose-
dependent manner with an IC50 value of 1.10 μM
(Fig. 4c). Significant inhibition of survival of PANC-1,
MiaPaCa-2, BxPC-3, and Pan02 cells was only observed
at concentrations greater than 1 μM.
FRAX597 synergises with gemcitabine in inhibiting
pancreatic cancer cell growth
Gemcitabine alone inhibited proliferation in all pancre-
atic cancer cell lines (Fig. 5a-e) in a dose-dependent
manner, with IC50 values between 5 nM for BxPC-3 cells
and 80 nM for Pan02 cells (Table 2). A further reduction
in proliferation was observed in all pancreatic cancer
cell lines (Fig. 5a-e) when FRAX597 was combined
with gemcitabine, compared to gemcitabine alone. The
Fig. 2 PAK1 knock-down (KD) inhibits proliferation and increases gemcitabine sensitivity. PANC-1 (a) and MiaPaCa-2 (b) PAK1 KD cells were
generated using shRNA transfection. As detected by western blot, clones 2.05 and 2.10; and clones 3.09 and 3.12 for PANC-1 and
MiaPaCa-2, respectively, expressed significantly less PAK1 than negative control (NC) clones, which had been transfected with a scrambled
shRNA. The proliferation rate of the KD clones for both PANC-1 (c) and MiaPaCa-2 (d), measured by thymidine incorporation, was significantly
lower after 96 h. Sensitivity of the KD clones to gemcitabine (20 nM and 50 nM for PANC-1 (e), and 50nM and 100nM for MiaPaCa-2 (f)) was
significantly increased. The data represent mean ± SEM, summarised from three independent experiments. * p < 0.05; ** p < 0.01, *** p < 0.001,
compared to either NC clone (only the higher p value of the two is presented)
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combination index, calculated for all pancreatic cancer
cell lines (Fig. 5f ), was less than 1, indicating that the
effect was synergistic.
Inhibition of pancreatic cancer cell growth by FRAX597
and gemcitabine is associated with reduced amounts of
active PAK1
The total amount of PAK1 and the amount of active
phospho-PAK1 were measured using western blot after
treatment with FRAX597 or gemcitabine, or the com-
bination of FRAX597 and gemcitabine. The amount of
active PAK1 was significantly reduced when treated with
FRAX597 alone compared to control in all pancreatic
cancer cell lines without affecting the amount of total
PAK1 (Fig. 6a-e). No effect on PAK1 expression was
observed after treatment with gemcitabine alone. For
MiaPaCa-2 cells (Fig. 6b) and BxPC-3 cells (Fig. 6c),
combined treatment with FRAX597 and gemcitabine re-
sulted in significant further reduction of active PAK1
compared to the FRAX597 treatment alone. In contrast,
in the other cell lines PANC-1 (Fig. 6a), Pan02 (Fig. 6d)
and LM-P (Fig. 6e), no further reduction in active PAK1
expression was observed following the combination
treatment.
FRAX597 and gemcitabine inhibit pancreatic tumour
growth in an orthotopic murine model
The tumour take rate was 100 % for both pancreatic
head and pancreatic tail models. The survival rate fol-
lowing surgery was 100 % for the pancreatic tail model
and over 95 % for the pancreatic head model. No differ-
ence in tumour volume was observed for mice treated
Table 1 PAK1 knock-down (KD) inhibits proliferation and
increases gemcitabine sensitivity
Growth rate (%/h) Gemcitabine IC50 (nM)
PANC-1 MiaPaCa-2 PANC-1 MiaPaCa-2
NC1 2.4 2.9 26 ± 2 29 ± 1
NC2 2.6 2.7 39 ± 1 28 ± 1
KD1 1.9 * 2.0 ** 20 ± 2 ** 26 ± 1 *
KD2 2.1 * 2.1 ** 21 ± 2 * 25 ± 2 *
NC1 and NC2 indicate PANC-1 NC clones NC1 and NC2; and MiaPaCa-2 NC
clones NC2 and NC8 respectively. KD1 and KD2 indicate PANC-1 KD clones
2.05 and 2.10; and MiaPaCa-2 KD clones 3.09 and 3.12 respectively. * p < 0.05;
** p < 0.01, compared to either NC clone (only the higher p value of the two
is presented)
Fig. 3 PAK1 knock-down (KD) inhibits expression of AKT and HIF1α. Expression of phospho-AKT (pAKT) was significantly reduced in the PAK1 KD
clones: 2.05 and 2.10 (PANC-1 (a)); and 3.09 and 3.12 (MiaPaCa-2 (b)), compared to the negative controls (NC), as assessed by western blot. HIF1α
expression was reduced in PANC-1 (c) and MiaPaCa-2 (d) PAK1 KD clones under normoxia and hypoxia (1 % O2) conditions. The data represent
mean ± SEM, summarised from three independent experiments. * p < 0.05; ** p < 0.01, *** p < 0.001, compared to either NC clone (only the higher
p value of the two is presented)
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with control or FRAX597 alone. Mice treated with gem-
citabine alone had significantly reduced tumour volume
when compared to control or FRAX597 alone, and a fur-
ther significant reduction in tumour volume was ob-
served for the mice treated with the combination of
FRAX597 and gemcitabine (Fig. 7a). A similar trend was
found when mice were evaluated for the presence of
peritoneal carcinomatosis. 43 % of mice in the combined
treatment group had peritoneal carcinomatosis com-
pared to 71 % of mice in the gemcitabine treatment
group, and 100 % of mice in the control and FRAX597
treatment groups (Fig. 7b).
Survival of mice in the combination treatment group
was significant increased compared to the control group,
as assessed by a stratified Cox regression analysis (Fig. 7c).
A rates ratio of 7 was calculated, indicating that mice in
the control group had a mortality rate 7 times greater than
mice in the combination treatment group (Table 3). The
rates ratio of 2.7 for mice in the gemcitabine alone
group, compared to mice in the combination treat-
ment group, was not statistically significant (p = 0.09).
Discussion
Our finding that PAK1 is expressed in pancreatic cancer
is in agreement with previous studies [8, 17]. We
confirmed that PAK1 was not expressed in normal pan-
creatic acinar or ductal cells, which are the likely pro-
genitors of pancreatic cancer [18]. In contrast, PAK1
was expressed in the tumour tissue, in which the pancre-
atic ductal adenocarcinomas cells stained positive
(Fig. 1a). All pancreatic cancer cell lines showed upregu-
lation of PAK1 compared to the normal pancreas cell
line, HPDE, regardless of Kras mutational status. The
observation from BxPC-3 and Pan02, that are Kras
wildtype cell lines, indicates that non-Kras mecha-
nisms may result in the activation of PAK1. Further
investigation will be required to elucidate those mecha-
nisms [19, 20]. The emergence of PAK1 expression im-
plies that PAK1 is involved in pancreatic carcinogenesis,
however, its role and therapeutic potential have not been
fully elucidated.
Fig. 4 FRAX597 inhibits proliferation, migration/invasion, and survival. The effect of the selective group 1-PAK inhibitor FRAX597 on cell proliferation (a),
cell migration/invasion (b) and cell survival (c) of the indicated human pancreatic cancer cell lines was measured using the thymidine-incorporation
method, the Transwell Boyden chamber assay, and the thymidine-withdrawal method, respectively. The values for the untreated cells were taken as
100 %. The data represent mean ± SEM, summarised from three independent experiments. Significance is not shown for clarity
Table 2 IC50 values for inhibition of proliferation and migration/
invasion by FRAX597, and of proliferation by gemcitabine
FRAX IC50
proliferation (μM)
FRAX IC50 migration/
invasion (nM)
Gemcitabine IC50
proliferation (nM)
PANC-1 2.0 ± 0.2 290 ± 70 33 ± 3
MiaPaCa-2 1.4 ± 0.4 105 ± 10 30 ± 3
BxPC-3 0.65 ± 0.1 330 ± 45 5 ± 1
Pan02 1.4 ± 0.1 605 ± 80 80 ± 10
LM-P 1.1 ± 0.2 150 ± 25 16 ± 2
IC50 values were obtained by fitting the data in Fig. 3 and Additional file 2:
Figure S2 using Sigmaplot
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Reduction of PAK1 expression by shRNA knock-down
(Fig. 2a-b) inhibited proliferation of the PANC-1 and
MiaPaCa-2 pancreatic cancer cell lines (Fig. 2c-d), likely
through modulation of the AKT pathway. These two hu-
man cell lines were chosen based on the PAK1 activity
where PANC-1 is considered ‘high’ activity whilst
MiaPaCa-2 is considered ‘low’ activity (Fig. 1b). This dif-
ference may contribute to the contrasting results in cell
survival where a reduction was observed in PANC-1
PAK1 KD cells (Additional file 1: Figure S1A) but not in
MiaPaCa-2 PAK1 KD cells (Additional file 1: Figure S1B).
The suggestion that ‘high’ PAK1 expressing cells may be
driving cell survival whereas ‘low’ PAK1 expressing cells
may rely on other mechanisms to drive cell survival re-
quires further investigation. The reduction in cell growth
in PAK1 KD cells was associated with a decrease in AKT
activity (Fig. 3a-b), but not in ERK activity (Additional
file 1: Figure S1C-D). Our group has previously found
that PAK1 mediated growth of colorectal cancer cell
lines by both ERK and AKT pathways [14], while an-
other group has found that PAK1 signalled preferen-
tially through the ERK pathway to control skin cancer
growth [11]. Thus, PAK1 signalling through AKT and
ERK pathways is dependent on the cancer type, and
our study suggests that PAK1 mediates pancreatic can-
cer cell growth through the AKT pathway rather than
the ERK pathway.
PAK1 may play a role in the resistance of pancreatic
cancer to hypoxia through regulation of HIF1α. The
transcription factor HIF1α regulates oxygen delivery and
a
c
e
b
d
f
Fig. 5 FRAX597 synergises with gemcitabine to inhibit proliferation. The effects of gemcitabine alone (Gem, solid bars), and gemcitabine after 20 h
pre-treatment with FRAX597 (Gem+ FRAX, striped bars), on proliferation of PANC-1 (a), MiaPaCa-2 (b), BxPC-3 (c), Pan02 (d), and LM-P (e) cells were
assessed by thymidine incorporation. The concentration of FRAX597 used was based on the IC50 value determined in Fig. 4a. The combination
index (CI), calculated by the Chou-Talalay method, was used to determine the mechanism of action of FRAX597 and gemcitabine (f). A value < 1
indicates synergistic inhibition. The data represent mean ± SEM, summarised from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001,
compared to control or untreated cells. # p < 0.05, ## p < 0.01, ### p < 0.001 compared to the corresponding gemcitabine treatment
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metabolic adaptation to hypoxia and has been found to
be a prognostic marker for pancreatic cancer [21]. Pan-
creatic tumours are known to be highly hypoxic, as they
feature a dense desmoplastic reaction (stroma), which
may contribute to pancreatic cancer invasion, metastasis,
and resistance to therapy [22]. Thus, mediators of sur-
vival in response to a hypoxic challenge are attractive
therapeutic targets for pancreatic cancer. Although, as
far as we are aware, this is the first study to examine
HIF1α as a downstream effector of PAK1 in pancreatic
cancer, PAK1 has previously been linked to HIF1α in
colorectal cancer [23]. The ability of PAK1 to contribute
to pancreatic carcinogenesis via multiple signalling path-
ways enhances its potential as a therapeutic target.
PAK1 knock-down also enhanced the sensitivity of
PANC-1 and MiaPaCa-2 cells to gemcitabine (Fig. 2e-f ),
as revealed by comparison of the IC50 values for inhib-
ition of proliferation between control and knock-down
a
c
b
d
e
Fig. 6 FRAX597 and gemcitabine reduce PAK1 activity. Expression of phospho-PAK1 (pPAK1) and PAK1 was measured in PANC-1 (a), MiaPaCa-2 (b),
BxPC-3 (c), Pan02 (d), and LM-P (e) cells in the presence of FRAX597 (FRAX), gemcitabine (Gem), or the combination of FRAX597 and gemcitabine
(Gem+ FRAX) using western blot. Variations in protein loading were corrected by GAPDH expression, and the values for untreated control cells were
taken as 100 %. The data represent mean ± SEM, summarised from three independent experiments. ** p < 0.01, *** p < 0.001, compared to control or
untreated cells. ~ p < 0.05, ~ ~ p < 0.01 compared to FRAX597 treatment
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clones (Table 1). Although gemcitabine remains a stand-
ard monotherapy treatment for pancreatic cancer pa-
tients, combining treatments with gemcitabine with the
goal of decreasing chemotherapy-associated cytotoxicity
and chemo-resistance and increasing survival has had
varied results [3]. Previous studies have found that the
PAK1 downstream effectors AKT and HIF1α could play
a role in gemcitabine resistance through NFκB which
limits gemcitabine uptake by decreasing nucleoside
transporters such as hENT and hCNT [3]. Furthermore,
PAK1 has been shown to regulate NFκB transcription
upstream of fibronectin regulation in pancreatic cancer
[8]. Although further investigation is required, the data
presented herein supports the use of a PAK1 inhibitor
combined with gemcitabine to limit gemcitabine cyto-
toxicity and chemo-resistance.
The group 1 PAK-selective inhibitor FRAX597 inhib-
ited proliferation, migration/invasion, and survival of all
pancreatic cancer cell lines tested (Fig. 4a-c). Although
FRAX597 also inhibits other kinases such as RET, YES1,
TEK, and CSF1R [12], the similar results obtained in the
PAK1 knock-down experiments suggest that in this case
PAK1 is indeed the relevant target. Furthermore, the
IC50 values for proliferation are similar to the value ob-
served in NF2-null Schwann cells [12]. However, the
IC50 values for either proliferation or migration/invasion
did not significantly correlate with the amount of active
PAK1 in the pancreatic cancer cells (data not shown).
This observation suggests that there may be a barrier
(e.g. uptake at the cell membrane) that prevents realisa-
tion of the full potential for inhibition in intact cells.
The presence of such a barrier could have contributed
to the failure to detect any difference in tumour volume
between the FRAX597-treated mice and the control
mice in our in vivo study. Furthermore, the dense des-
moplastic reaction may have also prevented the drug’s
uptake by the tumour. These observations illustrate the
importance of the microenvironment in assessment of a
drug’s efficacy, as the in vitro cell culture conditions may
not fully mimic the clinical setting.
Combination of the PAK1 inhibitor, FRAX597, with
gemcitabine resulted in increased inhibition of PAK1
Fig. 7 FRAX597 combined with gemcitabine inhibits tumour volume and increases survival in vivo. Pan02 murine pancreatic cancer cells were
injected orthotopically into the tail (a-b) or head (c) of the pancreas of C57/Bl6 mice. Mice were treated with saline (control; CT), FRAX597 (FRAX),
gemcitabine (Gem), or FRAX597 and gemcitabine (Gem + FRAX) at the doses given in the Materials and Methods section by intraperitoneal
injection. Mice were euthanased after 30 days for the orthotopic pancreatic tail model and tumour volumes were measured (a), and scored for
the presence of peritoneal carcinomatosis, or peritoneal spread (b). For assessment of survival, mice were euthanased after achieving a poor
health score and the time to euthanasia plotted as a collated Kaplan-Meier curve (c). The data represent mean ± SEM. * p < 0.05, *** p < 0.001,
compared to control. # p < 0.05 compared to gemcitabine treatment. ^^^ p < 0.001 compared to combination treatment (Gem + FRAX) using
stratified Cox regression analysis
Table 3 FRAX597 combined with gemcitabine increases survival
in a mouse orthotopic pancreatic cancer model
Treatment Rates ratio 95 % CI P value
Control 7.0 1.8 ± 27.0 0.005
Gemcitabine 2.7 1.0 ± 8.7 0.09
Gemcitabine + FRAX 1.0 (ref)
The overall statistics for the stratified Cox regression analysis were:
χ2 (2) = 9.9, p = 0.007
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activity in some, but not all, of the pancreatic cancer cell
lines tested (Fig. 6a-e). In all the pancreatic cancer cell
lines tested, PAK1 activity was significantly decreased
after treatment with FRAX597 alone, but no change in
activity was observed after treatment with gemcitabine
alone. Thus, combined treatment with FRAX597 and
gemcitabine might be expected to inhibit PAK1 to the
same extent as FRAX597 treatment alone, as was ob-
served for PANC-1, Pan02 and LM-P cells. The signifi-
cantly greater inhibition observed in MiaPaCa-2 and
BxPC-3 cells after combination treatment provided clear
evidence for synergy, although the mechanism for this is
unclear. Interestingly, these two pancreatic cancer cell
lines had the lowest phospho-PAK1 expression of all the
pancreatic cancer cell lines tested. This observation sug-
gests that phospho-PAK1 may be a predictive marker for
gemcitabine response, as has recently been shown for
PAK4 in pancreatic cancer [24].
Treatment with FRAX597 combined with gemcitabine
significantly decreased tumour volume in vivo (Fig. 7a)
and revealed a promising trend towards decreasing me-
tastasis (Fig. 7b) and increasing survival (Fig. 7c). Fur-
thermore, Ki67 staining of the tumours indicated that
the difference in tumour volume was due to inhibition
of proliferation (Additional file 2: Figure S2). Although
liver metastasis is often observed in the orthotopic pan-
creatic tail murine model, a total of only three mice,
from control and FRAX treatment groups, had liver me-
tastases at sacrifice, so no comparison could be under-
taken [16]. However, peritoneal carcinomatosis, or
peritoneal spread, was present and was compared. As a
difference in tumour volume was observed between ani-
mals treated with gemcitabine alone or with the combin-
ation of FRAX597 and gemcitabine, a decrease in
peritoneal carcinomatosis and an increase in survival
was expected, but significance was not reached. This
may be due to the fact that the study was stopped early,
before all mice were euthanised because of tumour-
related illness. Although the potential clinical value of
FRAX597 and the likely therapeutic benefit of targeting
PAK1 are clearly established by the data in Fig. 4, longer
studies are needed for a complete picture of the possible
survival benefits of combination treatment.
Conclusion
PAK1 is upregulated in human pancreatic cancer.
Knock-down experiments indicated that PAK1 is re-
quired for proliferation and survival of human pancre-
atic cancer cell lines through AKT- and/or HIF1α-
dependent pathway(s). Furthermore, PAK1 knock-down
sensitised pancreatic cancer cells to gemcitabine. A
group 1 PAK-specific inhibitor, FRAX597, inhibited pro-
liferation, migration/invasion, and survival of human
pancreatic cancer cell lines. When combined with
gemcitabine, FRAX597 synergistically inhibited pancre-
atic cancer growth in vitro and in vivo. This study sug-
gests the promise of inhibiting PAK1 function and
defines areas for further investigation to clarify its poten-
tial value as a target for pancreatic cancer therapy.
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Additional files
Additional file 1: Figure S1. PAK1 Knock-down (KD) effects on survival
and ERK expression. PAK1 KD cells were measured in the presence
(darker bars) and absence (lighter bars) of FBS to measure survival,
using thymidine-withdrawal. Survival in PANC-1 PAK1 KD clones (A) was
significantly lower but no difference was observed in MiaPaCa-2 PAK1 KD
clones (B). No reduction in the expression of either phospho-ERK (pERK1/2)
or total ERK (ERK1/2) was detected in either PANC-1 (C) or MiaPaCa-2 (D)
PAK1 KD cells, as assessed by western blot. The data represent mean ± SEM,
summarised from three independent experiments. *** p < 0.001, compared
to the corresponding clone with FBS. (PPTX 433 kb)
Additional file 2: Figure S2. FRAX597 and gemcitabine decreased Ki67
staining on orthotopic pancreatic tail tumours. Pan02 murine pancreatic
tumours from the orthotopic pancreatic tail tumour model treated with
saline (control; CT), FRAX597 (FRAX), gemcitabine (Gem), or FRAX597 and
gemcitabine (Gem + FRAX) at the doses given in the Materials and
Methods section, were fixed and stained for the proliferative marker, Ki67.
Three representative images were taken from each treatment group.
(PPTX 2275 kb)
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